Aquestive Therapeutics, Inc. Proceeds from Issuance of Debt
Aquestive Therapeutics, Inc. (AQST) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2025-03-05
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2020-12-31 was $0.00.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2019-12-31 was $0.00.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2018-12-31 was $0.00.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for the quarter ending 2018-09-30 was $0.00.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for fiscal 2023 was $31.14M.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for fiscal 2022 was $0.00.
- Aquestive Therapeutics, Inc. proceeds from issuance of debt for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
| Period end | Proceeds from Issuance of Debt 1 month | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-05 | ||||
| 2023-12-31 | $31.14M 10-K · filed 2025-03-05 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-05 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 10-K · filed 2021-03-09 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $70.00M 10-K · filed 2021-03-09 | |||
| 2019-09-30 | $70.00M 10-Q · filed 2020-11-04 | ||||
| 2019-07-31 | $13.11M 10-Q · filed 2020-11-04 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-09-04 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $5.00M 10-K · filed 2019-03-14 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $5.00M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $5.00M 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |